Quadrant Capital Group LLC Cytek Biosciences, Inc. Transaction History
Quadrant Capital Group LLC
- $2.65 Billion
- Q1 2025
A detailed history of Quadrant Capital Group LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,594 shares of CTKB stock, worth $4,271. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,594
Previous 99
1510.1%
Holding current value
$4,271
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CTKB
# of Institutions
159Shares Held
73.8MCall Options Held
600Put Options Held
4.9K-
Black Rock Inc. New York, NY17.1MShares$45.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.62MShares$25.8 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.46MShares$20 Million0.93% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$17.8 Million0.82% of portfolio
-
State Street Corp Boston, MA4.38MShares$11.7 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $361M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...